NO20032613D0 - Farmasöytisk sammensetning som har en forbedret vannopplöselighet - Google Patents

Farmasöytisk sammensetning som har en forbedret vannopplöselighet

Info

Publication number
NO20032613D0
NO20032613D0 NO20032613A NO20032613A NO20032613D0 NO 20032613 D0 NO20032613 D0 NO 20032613D0 NO 20032613 A NO20032613 A NO 20032613A NO 20032613 A NO20032613 A NO 20032613A NO 20032613 D0 NO20032613 D0 NO 20032613D0
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
water solubility
improved water
improved
solubility
Prior art date
Application number
NO20032613A
Other languages
English (en)
Other versions
NO20032613L (no
Inventor
Yohko Akiyama
Satoshi Iinuma
Hiroto Bando
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20032613D0 publication Critical patent/NO20032613D0/no
Publication of NO20032613L publication Critical patent/NO20032613L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20032613A 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret vannlöselighet NO20032613L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375601 2000-12-11
PCT/JP2001/010768 WO2002048141A1 (en) 2000-12-11 2001-12-10 Medicinal compositions improved in solublity in water

Publications (2)

Publication Number Publication Date
NO20032613D0 true NO20032613D0 (no) 2003-06-10
NO20032613L NO20032613L (no) 2003-08-05

Family

ID=18844590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032613A NO20032613L (no) 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret vannlöselighet

Country Status (10)

Country Link
US (1) US20040058956A1 (no)
EP (1) EP1350792A1 (no)
KR (1) KR20040025880A (no)
CN (1) CN1487935A (no)
AU (1) AU2002221096A1 (no)
CA (1) CA2431319A1 (no)
HU (1) HUP0401811A2 (no)
NO (1) NO20032613L (no)
PL (1) PL362979A1 (no)
WO (1) WO2002048141A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
NZ531890A (en) 2002-02-28 2006-02-24 Japan Tobacco Inc Ester compound and medicinal use thereof
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
US8105630B2 (en) * 2003-04-29 2012-01-31 Kowa Co., Ltd. Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
JPWO2006137595A1 (ja) * 2005-06-24 2009-01-22 武田薬品工業株式会社 Her2発現癌の予防・治療薬
CN101233130A (zh) * 2005-09-30 2008-07-30 霍夫曼-拉罗奇有限公司 二嗪唑衍生物,它们的制备和作为药剂的应用
KR100767349B1 (ko) * 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
UA109109C2 (uk) * 2009-01-15 2015-07-27 Сефалон, Інк. Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
EP2581084A4 (en) * 2010-05-31 2014-06-25 Astellas Pharma Inc SOLID DISPERSION COMPRISING A TRIAZOLE COMPOUND
ES2836809T3 (es) 2010-11-24 2021-06-28 Melinta Subsidiary Corp Composiciones farmacéuticas
BR122020010643B1 (pt) * 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CA2903871A1 (en) * 2013-03-15 2014-09-18 Aerpio Therapeutics Inc. Formulations with increased solubility of compounds that activate tie-2
CN106232144B (zh) 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5352617A (en) * 1976-10-25 1978-05-13 Shin Etsu Chem Co Ltd Solid drug coating composition
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
EP0925294B3 (en) * 1996-07-24 2018-07-04 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
WO1998051281A1 (fr) * 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Preparations a base de suspensions aqueuses possedant d'excellentes proprietes de redispersion

Also Published As

Publication number Publication date
KR20040025880A (ko) 2004-03-26
HUP0401811A2 (hu) 2004-12-28
PL362979A1 (en) 2004-11-02
AU2002221096A1 (en) 2002-06-24
NO20032613L (no) 2003-08-05
EP1350792A1 (en) 2003-10-08
CN1487935A (zh) 2004-04-07
US20040058956A1 (en) 2004-03-25
WO2002048141A1 (en) 2002-06-20
CA2431319A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
NO20032613D0 (no) Farmasöytisk sammensetning som har en forbedret vannopplöselighet
ITTO20000779A0 (it) Composizioni farmaceutiche.
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
DE50104135D1 (de) Wässrige zusammensetzungen
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20030153L (no) Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet
ATE303787T1 (de) Schergelzusammensetzungen
DK1524266T3 (da) Farmaceutisk sammensætning
DK1294644T3 (da) Vandbehandlingssammensætninger
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20026175L (no) Vaksinesammensetning
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
AR028197A1 (es) Composiciones antitranspirantes
MXPA03001425A (es) Compuestos farmaceuticos.
NO20026123L (no) Farmasöytiske sammensetninger
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
DE60139499D1 (de) Reinigungsmittelzusammensetzungen
NO20031095L (no) Farmasoytiske sammensetninger
NO20013441D0 (no) Sammensetninger som har forbedret stabilitet
DK1263734T3 (da) 3-thiomethylpyrazoler som pesticider
ATE266316T1 (de) Fungizide zusammensetzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application